需求名稱：阿奇霉素顆粒（0.1g/袋）參比制劑備案的綜述資料 具體要求： 1.備案參比制劑為阿奇霉素干混懸劑原研地產(chǎn)化由輝瑞制藥有限公司生產(chǎn)，商品名：希舒美，規(guī)格：0.1g/包。 2.按照最新法規(guī)要求起草綜述資料 《參比制劑遴選申請資料》。 3.說明銷售數(shù)據(jù)來源。 4.查詢的數(shù)據(jù)最后有截屏或來源。 5.其他事項(xiàng)再溝通。 要求時(shí)間：請?jiān)?020年01月10日之前 交稿方式：直接點(diǎn)擊交稿在線交稿就是了，我會每天過來看的，謝謝各位藥智的戰(zhàn)友們   [更多]

求購British Pharmacopoeia (Veterinary): Chlortetracycline Veterinary Oral Powder《BP2019》的藥典標(biāo)準(zhǔn)一份   [更多]

中藥新藥的藥學(xué)實(shí)驗(yàn)室設(shè)計(jì)圖紙，不包括藥理毒理、臨床，只做藥學(xué)資料用。（設(shè)備清單、SOP、人員建制也可一并提供）根據(jù)您提供的內(nèi)容詳細(xì)完整和詳細(xì)程度，可提高報(bào)酬。   [更多]

需求內(nèi)容在圖片里面   [更多]

文獻(xiàn)： 1、" Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. " Pharmacotherapy 2007;27:290–8. Page RL, Schwiesow J, Hilts A. 2、Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013;39:310–24. Vehreschild JJ, Birtel A, Vehreschild MJGT, et al. 3、Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99. 4、J Med Chem, 51: 4632～4640. Org. Process Res. Dev. 2019, 23, 9, 2057-2068 Pharmazie 73(9):494-497 · September 2018 5、中國醫(yī)藥工業(yè)雜志 2012， 43（8）， 644-646 6、精細(xì)化工中間體2013，43（2），46-48 7、精細(xì)化工中間體2011，41（4），46-48 8、中國現(xiàn)代應(yīng)用藥學(xué)2011，28（1），58-59 9、Chemical biology&Drug Design 2014, 83(3), 306-316 10、Letters in organic chemistry 2012, 9(4), 276-279 11、Medicines Evidence Commentary : Chronic kidney disease: calcium-based versus non-calcium-based phosphate binders Source: National Institute for Health and Care Excellence - NICE - 21 January 2014 - Publisher: National Institute for Health and Care Excellence (NICE) 12、double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children 13、J. Med. Chem. 2018, 61, 5304?5322. 14、Chem. Biol. Drug Des. 2014, 83, 306?316. 15、J. Pharm. Biomed. Anal. 2009, 50, 144?150. 16、Int. J. Pharm. Sci. 2016, 8, 97?102. 17、J. Pharm. Biomed. Anal. 2010, 52, 493?507. 18、Org. Process Res. Dev. 2013, 17, 1036?1041. 19、Beilstein J. Org. Chem. 2011, 7, 442? 495. 20、Bioorg. Med. Chem. Lett. 2014, 24, 1108?1110. 21、New Activated PEG Derivatives for Affinity Partitioning 22、Population incidence and mortality of sepsis in an urban African setting 2013-2016 23、Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in   [更多]

急需冷敷凝膠、冷敷貼及傷口敷料的一類醫(yī)療器械全套備案申請資料   [更多]

求助西地那非原料藥信息   [更多]

提供藥廠及藥品轉(zhuǎn)讓項(xiàng)目/合作項(xiàng)目，需要具體的轉(zhuǎn)讓信，企業(yè)名稱，聯(lián)系方式，信息需真實(shí)可靠。   [更多]

EP10.0藥典： 1、Piperacillin Sodium EP10.0 2、替加環(huán)素Tigecycline EP10.0 3、阿托品atropine EP10.0 4、硫酸阿托品 EP10.0 5、2.6.31 EP10.0 6、EP10.0: Salmeterol Xinafoate 7、EP10.0: Preparations for inhalation 8、EP10.0: Pressurised pharmaceutical preparations" 9、EP10:ceftazidime 10、Formoterol Fumarate EP10.0 11、乳酸依沙吖啶Ethacridine lactate monohydrate EP10.0 12、Aspartame的EP10.0標(biāo)準(zhǔn) 13、EP10.0 3.1.9 14、perindopril tert-butylamine的EP10.1標(biāo)準(zhǔn) 15、CALCIUM LEVOFOLINATE HYDRATE EP10.0 16、Deslanoside EP10 17、Inhalation powders EP10 18、Fluconazole EP10 19、Nifedipine EP10 20、Calcium Dobesilate Monohydrate 羥苯磺酸鈣原料藥EP10.0的標(biāo)準(zhǔn) 21、EP10.0 Ipratropium bromide 22、Voriconazole EP10.0 23、Magnesium Stearate硬脂酸鎂 EP10.0 24、Colloidal Anhydrous Silica膠態(tài)無水二氧化硅 EP10.0 25、Purified water 純化水 EP10.0 26、Povidone (K-90) 聚維酮 (K-90) EP10.0 27、Hydroxypropyl cellulose (EF)羥丙纖維素 (EF) EP10.0 28、HPMC E-15羥丙甲纖維素E-15 EP10.0 29、Purified Talc 滑石粉 EP10.0 30、Pregelatinised Starch 預(yù)膠化淀粉 EP10.0 31、Lactose Monohydrate一水乳糖 EP10.0 32、lsopropyl Alcohol異丙醇 EP10.0 33、Titanium dioxide二氧化鈦 EP10.0 34、Polyethylene glycol 400 聚乙二醇400 EP10.0 35、氨丁三醇 TROMETAMOL EP10.0 36、依地酸鈣鈉 SODIUM CALCIUM EDETATE EP10.0 37、碘帕醇 IOPAMIDOL EP10.0 38、甘露醇 MANNITOL 查EP10.0 39、Macrogol 4000 EP10.0 40、鹽酸二甲雙胍Metformin hydrochloride，EP10.0 41、Polyoxyl castor oil EP10.0 42、Ascorbic Acid-EP10.0 43、EP10.0中的（5.1.8） 44、EP10.0中的（5.1.4） 45、Carboxymethylcellulose sodium的最新歐洲藥典，然后這個(gè)monograph（專著）里面有一個(gè)取代度的具體方法。 EP10.0 46、Tranexamic Acid EP10.0 47、歐洲藥典10.0版Starches hydrocyethyl 48、Dextrose和Glucose monohydrate EP10標(biāo)準(zhǔn) 49、Oxcarbazepine EP10標(biāo)準(zhǔn) 50、Human albumin solution EP10標(biāo)準(zhǔn) 51、Cefoperazone Sodium EP10.0 52、Sulbactam Sodium EP10.0 53、Azithromycin、 EP10標(biāo)準(zhǔn) 54、Aripiprazole EP10.0 55、 Candesartan cilexetil EP10.0 56、Clopidogrel besilate EP10.0 57、Clopidogrel hydrogen sulfate EP10.0 58、Clopidogrel hydrochloride EP10.0 59、Duloxetine hydrochloride EP10.0 60、Galantamine hydrobromide EP10.0 61、Irbesartan EP10.0   [更多]

1、Ophthalmic viscosurgical devices Article· Literature Review?in?Current Opinion in Ophthalmology 19(1):50-4 · February 2008?with?82 Reads DOI: 10.1097/ICU.0b013e3282f14db0 · Source: PubMed 2、Lancet Psychiatry. 2019 Mar;6(3):211-224. doi: 10.1016/S2215-0366(18)30511-X. Epub 2019 Feb 18. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Huang Y1, Wang Y2, Wang H3, Liu Z4, Yu X4, Yan J5, Yu Y6, Kou C6, Xu X7, Lu J7… PMID:30792114 3、Prevalence of myopia in local and international schools in Hong Kong. 4、Effects of different concentrations of atropine on controlling myopia in myopic children. 5、Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of rhesus monkeys 6、Effects of different concentrations of atropine on controlling myopia in myopic children. 7、Use of mechlorethamine gel in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): “Real-world” experience from the Prospective Observational Study (PROVe) 8、Safety and effectiveness of tolvaptan administration after total arch replacement Yasunori Iida, MD, PhD, Akihiro Yoshitake, MD, PhD, Hideyuki Shimizu, MD, PhD 9、The role of tolvaptan administration after cardiac surgery: ameta-analysisIoannis Bellos MD , Dimitrios C. Iliopoulos MD, PhD ,Despina N. Perrea MD, PhD 10、Comparative bioavailability and in vitro in vivo correlation of two sustained release brands of theophylline: tablets and pellets.Tulain U, Ur-Rahman N.Pak J Pharm Sci. 2008 Apr;21(2):131-8. 11、Relative bioavailability and bioequivalence study of theophylline sustained release formulations. Vergin H, Mahr G, Winterhalter B, Wigand R.Arzneimittelforschung. 2003;53(9):635-9. 12、Use of mechlorethamine gel in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): “Real-world” experience from the Prospective Observational Study (PROVe) 13、journal of medicinal chemistry 2004,47,530 14、Gupta AK, Ryder JE, Lynch LE et al. The use   [更多]